MX2020003004A - Cannabidiol transdermico sintetico para el tratamiento de epilepsia focal en adultos. - Google Patents
Cannabidiol transdermico sintetico para el tratamiento de epilepsia focal en adultos.Info
- Publication number
- MX2020003004A MX2020003004A MX2020003004A MX2020003004A MX2020003004A MX 2020003004 A MX2020003004 A MX 2020003004A MX 2020003004 A MX2020003004 A MX 2020003004A MX 2020003004 A MX2020003004 A MX 2020003004A MX 2020003004 A MX2020003004 A MX 2020003004A
- Authority
- MX
- Mexico
- Prior art keywords
- adults
- synthetic
- treatment
- cannabidiol
- focal epilepsy
- Prior art date
Links
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 title abstract 3
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 title abstract 3
- 229950011318 cannabidiol Drugs 0.000 title abstract 3
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 title abstract 3
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 title abstract 3
- 206010061334 Partial seizures Diseases 0.000 title 1
- 201000007186 focal epilepsy Diseases 0.000 title 1
- 206010010904 Convulsion Diseases 0.000 abstract 2
- 206010015037 epilepsy Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente tecnología se refiere a un método para reducir la frecuencia de las crisis de epilepsia en un sujeto que tiene epilepsia, por medio de la administración por la vía transdérmica de una cantidad eficaz de cannabidiol (CBD) al sujeto, en donde se reduce la frecuencia de las crisis de epilepsia.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762560446P | 2017-09-19 | 2017-09-19 | |
US201762593575P | 2017-12-01 | 2017-12-01 | |
US201862613160P | 2018-01-03 | 2018-01-03 | |
US201862652995P | 2018-04-05 | 2018-04-05 | |
US201862660198P | 2018-04-19 | 2018-04-19 | |
PCT/IB2018/057189 WO2019058261A1 (en) | 2017-09-19 | 2018-09-18 | TRANSDERMAL SYNTHETIC CANNABIDIOL FOR THE TREATMENT OF FOCAL EPILEPSY IN ADULTS |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020003004A true MX2020003004A (es) | 2020-11-06 |
Family
ID=63762572
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020003004A MX2020003004A (es) | 2017-09-19 | 2018-09-18 | Cannabidiol transdermico sintetico para el tratamiento de epilepsia focal en adultos. |
Country Status (11)
Country | Link |
---|---|
US (2) | US20190083388A1 (es) |
EP (1) | EP3684411A1 (es) |
JP (2) | JP2020534362A (es) |
KR (1) | KR20200055067A (es) |
AU (1) | AU2018337933A1 (es) |
BR (1) | BR112020004947A2 (es) |
CA (1) | CA3075719A1 (es) |
IL (2) | IL301910A (es) |
JO (1) | JOP20200045A1 (es) |
MX (1) | MX2020003004A (es) |
WO (1) | WO2019058261A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3733156A1 (de) * | 2019-05-02 | 2020-11-04 | Gábor Fóti | C.b.d.m therapie |
JP2022547136A (ja) * | 2019-09-17 | 2022-11-10 | ジナーバ・ファーマシューティカルズ・インコーポレイテッド | 発達性及びてんかん性脳症における行動障害の治療 |
EP4041209A4 (en) * | 2019-10-11 | 2024-01-24 | Pike Therapeutics Inc | TRANSDERMAL COMPOSITIONS CONTAINING CANNABIDIOL (CBD) FOR USE IN THE TREATMENT OF SEIZURE DISORDERS |
GB2597287A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
CA3187588A1 (en) * | 2020-08-17 | 2022-02-24 | Fotios M. Plakogiannis | Transdermal pharmaceutical formulations of cannabinoids |
EP4319730A1 (en) * | 2021-04-08 | 2024-02-14 | Pike Therapeutics, Inc. | Pharmaceutical composition and method for treating seizure disorders |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5801794B2 (ja) | 2009-04-28 | 2015-10-28 | ジネルバ ファーマシューティカルズ, インコーポレイティド | カンナビジオールの製剤及びその使用方法 |
ES2635084T3 (es) * | 2009-08-31 | 2017-10-02 | Zynerba Pharmaceuticals, Inc. | Uso de profármacos de cannabidiol en administración tópica y transdérmica con microagujas |
GB2530001B (en) * | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
GB2541191A (en) * | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
-
2018
- 2018-09-18 CA CA3075719A patent/CA3075719A1/en active Pending
- 2018-09-18 JO JOP/2020/0045A patent/JOP20200045A1/ar unknown
- 2018-09-18 US US16/133,930 patent/US20190083388A1/en not_active Abandoned
- 2018-09-18 BR BR112020004947-6A patent/BR112020004947A2/pt unknown
- 2018-09-18 AU AU2018337933A patent/AU2018337933A1/en active Pending
- 2018-09-18 IL IL301910A patent/IL301910A/en unknown
- 2018-09-18 EP EP18782520.3A patent/EP3684411A1/en active Pending
- 2018-09-18 KR KR1020207011219A patent/KR20200055067A/ko not_active Application Discontinuation
- 2018-09-18 MX MX2020003004A patent/MX2020003004A/es unknown
- 2018-09-18 JP JP2020537297A patent/JP2020534362A/ja active Pending
- 2018-09-18 WO PCT/IB2018/057189 patent/WO2019058261A1/en unknown
-
2020
- 2020-02-20 IL IL272818A patent/IL272818A/en unknown
- 2020-08-18 US US16/996,082 patent/US20210030665A1/en not_active Abandoned
-
2023
- 2023-09-08 JP JP2023145851A patent/JP2023171776A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2018337933A1 (en) | 2020-03-12 |
EP3684411A1 (en) | 2020-07-29 |
JP2023171776A (ja) | 2023-12-05 |
US20210030665A1 (en) | 2021-02-04 |
CA3075719A1 (en) | 2019-03-28 |
US20190083388A1 (en) | 2019-03-21 |
IL301910A (en) | 2023-06-01 |
IL272818A (en) | 2020-04-30 |
WO2019058261A9 (en) | 2019-07-04 |
KR20200055067A (ko) | 2020-05-20 |
JOP20200045A1 (ar) | 2020-02-27 |
JP2020534362A (ja) | 2020-11-26 |
WO2019058261A1 (en) | 2019-03-28 |
BR112020004947A2 (pt) | 2020-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20200045A1 (ar) | كانابيدْيُول تخليقي يتم تناوله عبر الأدمة لعلاج الصرع البؤري لدى البالغين | |
MX2020006954A (es) | Uso del cannabidiol en el tratamiento del complejo de esclerosis tuberosa. | |
PH12015502075B1 (en) | Treatment of cataplexy | |
PH12017500933A1 (en) | Sublingual administration of riluzole | |
MY194341A (en) | Method of treating a brain tumor | |
MX2020001757A (es) | Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades. | |
MX2022012424A (es) | Tratamiento del sindrome del cromosoma x fragil con canabidiol. | |
MX2016010504A (es) | Metodos para el tratamiento de pacientes con hipercolesterolemia que no esta controlada adecuadamente por una terapia con estatinas de dosis moderada referencia cruzada a solicitudes relacionas. | |
AU2016255707A8 (en) | Uses of cannabidiol for treatment of infantile spasms | |
MX2015009209A (es) | Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y metodos de tratamiento con los mismos. | |
PH12017500934A1 (en) | Sublingual formulation of riluzole | |
MX2022001697A (es) | Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos. | |
JOP20220054A1 (ar) | علاج اعتلال الدماغ syngap1 | |
MX2018004132A (es) | Método de tratamiento de meduloblastoma con un inhibidor de ezh2. | |
MX2016010085A (es) | Metodos para tratar lesion del cerebro leve. | |
WO2018209022A3 (en) | Methods of treating neuropsychiatric disorders | |
EA201690997A1 (ru) | Композиция для применения в лечении стойкого кашля | |
MX2016004967A (es) | Tratamiento para cancer pancreatico. | |
MX2015013186A (es) | Adminitracion craneal de productos farmaceuticos. | |
MX2017010654A (es) | Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres. | |
MX2019012659A (es) | Metodos para tratar ateroesclerosis con neutralizadores gamma-cetoaldehido. | |
MX2013011694A (es) | Analogos de taxano y abeo-taxanos. | |
MX2018001684A (es) | Metodo de curacion de heridas. | |
MX2023003924A (es) | Metodos de administracion de tratamiento antifibrotico. | |
EA201790220A1 (ru) | Лечение симптомов, связанных с андроген-депривационной терапией |